Sphere-9 VT

Study on Investigational Catheter for Scar-Related Ventricular Tachycardia

Recruiting
18 years - 85 years
All
Phase N/A
60 participants needed
1 Location

Brief description of study

Sphere-9 VT EFS is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, scar-related monomorphic ventricular tachycardia will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ventricular Tachycardia (VT)
  • Age: 18 years - 85 years
  • Gender: All

Inclusion Criteria:

  1. Any of the following:
    1. Ischemic cardiomyopathy (ICM) patients with prior history of myocardial infarction (MI).
    2. Non-ischemic cardiomyopathy (NICM) patients with documented myocardial scar in a territory without coronary stenosis as evidenced by cardiac imaging.
  2. At least one episode of sustained (continuous for >30 seconds or requiring ICD

    intervention for termination) monomorphic ventricular tachycardia within the 6 months prior to enrollment.

  3. Recurrence of sustained ventricular tachycardia despite class I or III antiarrhythmic drug therapy or ICD intervention.
  4. Implanted with an implantable cardiac defibrillator (ICD) or CRT-D for at least 3 months prior to the ablation procedure.
  5. Age 18 through 85 years old.
  6. Willing and able to provide informed consent.
  7. Willing and able to comply with all pre-, post-, and follow-up testing requirements.

Exclusion Criteria:

  1. Incessant VT necessitating hemodynamic support prior to the ablation procedure.
  2. Unstable polymorphic VT or ventricular fibrillation (VF).
  3. VTs due to any of the following:
    1. Idiopathic VT
    2. Automaticity or triggered activity
    3. Lamin or titin genetic mutation
    4. Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause (e.g., drug induced arrhythmia).
  4. NICM subjects with active inflammatory processes (e.g., myocarditis) within 120 days

    prior to the ablation procedure.

  5. VT or VF thought to be from channelopathies.
  6. More than two prior VT ablations at any time, more than one prior VT ablation within 12 months prior to the ablation procedure, or any VT ablation within 4 weeks prior to the ablation procedure.
  7. Sarcoidosis.
  8. Hypertrophic cardiomyopathy, except when due to an apical aneurysm.
  9. Unstable angina.
  10. Active myocardial ischemia.
  11. Type 1 myocardial infarction within 2 months (60 days) prior to the ablation procedure.
  12. Any percutaneous coronary intervention within 2 months (60 days) prior to the ablation procedure.
  13. Any cardiac surgery within 3 months (90 days) prior to the ablation procedure.
  14. Left ventricular ejection fraction (LVEF) <15%.
  15. NYHA Class IV heart failure.
  16. Decompensated heart failure.
  17. Currently receiving support, or anticipated to receive support prior to the index ablation procedure, via extracorporeal membrane oxygenation (ECMO).
  18. Ventricular assist device (VAD) implanted, planned or required for the procedure.
  19. Severe aortic or mitral stenosis, or severe aortic or mitral regurgitation.
  20. Presence of prosthetic valve in the aortic or mitral valve.
  21. Patients with advanced COPD (on home oxygen).
  22. Presence of intracardiac thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation.
  23. Thromboembolic event (stroke or transient ischemic attack) within 6 months (180 days) prior to the index ablation procedure or with neurologic deficit.
  24. Left atrium (LA) or left ventricle (LV) intracardiac thrombus on imaging.
  25. Severe bleeding, clotting or thrombotic disorder, or thrombocytopenia (defined as platelet count <80,000).
  26. Contraindication to anticoagulation.
  27. End-stage renal disease (requiring dialysis).
  28. Acute illness, active infection, or sepsis.
  29. Life expectancy less than 12 months.
  30. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence.
  31. Body mass index >45 kg/m2.
  32. Known ongoing drug or alcohol dependency.
  33. Current or anticipated participation in any other ongoing study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.
  34. Vulnerable subjects (such as a prisoner, handicapped or mentally disabled person, or person under tutelage or guardianship).
  35. Any other condition that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would pose a significant hazard to the subject if an ablation procedure were performed.

This study investigates the use of an investigational catheter and ablation system for individuals with scar-related monomorphic ventricular tachycardia.

The purpose of this study is to evaluate the feasibility of using the Sphere-9 Catheter and Affera Ablation System for treating this condition. The study will focus on assessing the safety and potential effectiveness of this investigational treatment.

  • Who can participate: Adults aged 18 to 85 years with a history of ischemic or non-ischemic cardiomyopathy and recurrent ventricular tachycardia may be eligible. Participants must have an implantable cardiac defibrillator and be able to provide informed consent.
  • Study details: Participants will undergo a procedure using the investigational catheter and Affera Ablation System.
Updated on 16 Jun 2026. Study ID: 24-2055

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center